About TussiCaps®
TussiCaps® is the first and only hydrocodone/chlorpheniramine FDA-approved capsule for the relief of cold-related cough in adults and children 6 years of age and older.
Just one TussiCaps® capsule suppresses cough for up to 12 hours.
- The antitussive activity of hydrocodone is greater than that of codeine 2
- Chlorpheniramine reduces the histamic response related to colds and allergies
The TussiCaps® combination of hydrocodone and chlorpheniramine (bioequivalent to Tussionex®) is proven effective. 3
Tussionex is a registered trademark of UCB Manufacturing, Inc.
IMPORTANT RISK INFORMATION
TussiCaps® (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsules are indicated for relief of cough and upper respiratory symptoms associated with allergy or cold in adults and children 6 years of age and older.
TussiCaps® is contraindicated in the presence of known allergy or sensitivity to hydrocodone or chlorpheniramine. The most common adverse reactions associated with TussiCaps® are sedation, drowsiness, and mental clouding, which may impair the mental and/or physical abilities required for potentially hazardous tasks. Overdose with hydrocodone-containing products has been associated with fatal respiratory depression.
are registered trademarks of Mallinckrodt Inc. TussiCaps logo is a trademark of Mallinckrodt Inc. COVIDIEN and COVIDIEN with Logo are trademarks of Covidien AG.